Clinical trial structures

Por Evans, Scott R.
Publicado em 2010

Common statistical concerns in clinical trials

Por Evans, Scott R.
Publicado em 2010

Fundamentals of clinical trial design

Por Evans, Scott R.
Publicado em 2010

Comment: Fundamentals and Innovation in Antibiotic Trials

Por Evans, Scott R., Follmann, Dean
Publicado no Stat Biopharm Res (2015)

Using Outcomes to Analyze Patients Rather than Patients to Analyze Outcomes: A Step toward Pragmatism in Benefit:risk Evaluation

Por Evans, Scott R., Follmann, Dean
Publicado no Stat Biopharm Res (2016)

Evaluating Anti-Infective Drugs in the Resistant Pathogen Setting: Can we Use External Controls?

Por Evans, Scott R, Powers, John
Publicado no Stat Commun Infect Dis (2017)

Methods and issues in studies of CRE

Por Evans, Scott R., Harris, Anthony D.
Publicado no Virulence (2016)

Comparison of Direct and Indirect Measurement of LDL-C in HIV-Infected Individuals: ACTG 5087

Por Evans, Scott R., Fichtenbaum, Carl J., Aberg, Judith A.
Publicado em 2007

A logrank test-based method for sizing clinical trials with two co-primary time-to-event endpoints

Por Sugimoto, Tomoyuki, Sozu, Takashi, Hamasaki, Toshimitsu, Evans, Scott R.
Publicado em 2013

Predicted Interval Plots (PIPS): A Graphical Tool for Data Monitoring of Clinical Trials

Por Li, Lingling, Evans, Scott R., Uno, Hajime, Wei, L.J.
Publicado em 2009

Group-Sequential Strategies in Clinical Trials with Multiple Co-Primary Outcomes

Por Hamasaki, Toshimitsu, Asakura, Koko, Evans, Scott R, Sugimoto, Tomoyuki, Sozu, Takashi
Publicado no Stat Biopharm Res (2015)

Group-sequential three-arm noninferiority clinical trial designs

Por Ochiai, Toshimitsu, Hamasaki, Toshimitsu, Evans, Scott R., Asakura, Koko, Ohno, Yuko
Publicado no J Biopharm Stat (2017)

Totality of outcomes: A different paradigm in assessing interventions for treatment of tuberculosis

Por Montepiedra, Grace, M. Yuen, Courtney, Rich, Michael L., Evans, Scott R.
Publicado no J Clin Tuberc Other Mycobact Dis (2016)

Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087

Por Fichtenbaum, Carl J., Yeh, Tzu-Min, Evans, Scott R., Aberg, Judith A.
Publicado em 2010

Vicriviroc and Peripheral Neuropathy: Results from AIDS Clinical Trials Group 5211

Por Yeh, Tzu-min, Evans, Scott R., Gulick, Roy M., Clifford, David B.
Publicado em 2010

Sample size determination in group-sequential clinical trials with two co-primary endpoints

Por Asakura, Koko, Hamasaki, Toshimitsu, Sugimoto, Tomoyuki, Hayashi, Kenichi, Evans, Scott R, Sozu, Takashi
Publicado em 2014

Difficulties in Demonstrating Superiority of an Antibiotic for Multidrug-Resistant Bacteria in Nonrandomized Studies

Por Eliopoulos, George M., Stafford, Kristen A., Boutin, Mallory, Evans, Scott R., Harris, Anthony D.
Publicado no Clin Infect Dis (2014)

Sample Size Considerations in Clinical Trials when Comparing Two Interventions using Multiple Co-Primary Binary Relative Risk Contrasts

Por Ando, Yuki, Hamasaki, Toshimitsu, Evans, Scott R., Asakura, Koko, Sugimoto, Tomoyuki, Sozu, Takashi, Ohno, Yuko
Publicado no Stat Biopharm Res (2015)

Clinical, laboratory, and neuroimaging characteristics of fatigue in HIV-infected individuals

Por Schifitto, Giovanni, Deng, Lijuan, Yeh, Tzu-min, Evans, Scott R., Ernst, Thomas, Zhong, Jianhui, Clifford, David
Publicado em 2010

Patterns of peripheral neuropathy in ART-naïve patients initiating modern ART regimen

Por Lee, Anthony J., Bosch, Ronald J., Evans, Scott R., Wu, Kunling, Harrison, Taylor, Grant, Philip, Clifford, David B.
Publicado no J Neurovirol (2015)